Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined...
ObvioHealth, a global Virtual Research Organization (VRO), is set to launch a first-of-its-kind clinical trial in A...
Futura Medical, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transde...
A £1.5 million grant from the UK's Medical Research Council (MRC) will support new research examining changes in h...
Zhaoke Ophthalmology has announced that the Phase III clinical trial of one of the company's core drug candidates, Cyclo...
Clinical trials in a drug development process often face multiple hurdles around patient recruitment and management resu...
Universities of Sheffield, Oxford, Liverpool, Newcastle, and Birmingham, with support from the UK Coronavirus Immunology...
Beneficial effects in autism spectrum disorders of the Japanese food supplement Nichi-Glucan (www.nichiglucan.com), a bi...
eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and ...
Medidata, a Dassault Systèmes company, announced the launch of the Medidata Decentralized Clinical Trials (D...
The International Vaccine Institute (IVI) in South Korea has announced that the Bill & Melinda Gates Foundation has ...
Tiziana Life Sciences plc, a UK based biotechnology company focused on innovative therapeutics for oncology, inflammatio...
Guangzhou Link Health Pharma Co., Ltd. (Link Health), based in China, and Australian firm George Clinical Pty Ltd (Georg...
FUJIFILM Toyama Chemical has announced the initiation of a new phase III clinical trial in Japan concerning its anti-inf...
TrialWire(TM), the most secure digital Patient Recruitment Platform for trial rescue, announces the launch of StudyBoost...
United Kingdom government announced an investment of 33.6 million pounds ($43.5 million) in a study called “h...
Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase...
In June 2020, Tychan began its Phase 1 clinical safety trials in humans to evaluate TY027, a monoclonal antibo...
